Role of the polyol pathway in high glucose-induced apoptosis of retinal pericytes and proliferation of endothelial cells

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 7, 2008, Pages 3216-3223

  Takamura, Yoshihiro ^a   Tomomatsu, Takeshi ^a   Kubo, Eri ^a   Tsuzuki, Syousai ^a   Akagi, Yoshio ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; FIDARESTAT; GLUCOSE; NEUTRALIZING ANTIBODY; POLYOL; TRANSFORMING GROWTH FACTOR BETA; ANTIBODY; POLYMER;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL GROWTH; CELL INTERACTION; CELL LOSS; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CELL VIABILITY; CHEMICAL ANALYSIS; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; GROWTH INHIBITION; IN VITRO STUDY; NONHUMAN; PERICYTE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA CELL; ANIMAL; CAPILLARY; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; RETINA BLOOD VESSEL; SWINE;

ALDEHYDE REDUCTASE; ANIMALS; ANTIBODIES; APOPTOSIS; CAPILLARIES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOTHELIAL CELLS; GLUCOSE; PERICYTES; POLYMERS; RETINAL VESSELS; SWINE; TRANSFORMING GROWTH FACTOR BETA;

EID: 48249083387     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1643     Document Type: Article

References (47)

1. Cogan DG, Kuwabara T. Capillary shunts in the pathogenesis of diabetic retinopathy. Diabetes. 1963;12:293-300.
2. Robison WG Jr, Tillis TN, Laver N, Kinoshita JH. Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp Eye Res. 1990;50:355-366.
3. Engerman RL, Kern TS. Experimental galactosemia produces diabetic-like retinopathy. Diabetes. 1984;33:97-100.
4. Kador PF, Akagi Y, Terubayashi H, Wyman M, Kinoshita JH. Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol. 1988;106:1099-1102.
5. Kador PF, Akagi Y, Takahashi Y, Ikebe H, Wyman M, Kinoshita JH. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol. 1990;108:1301-1309.
6. Akagi Y, Kador PF. Effect of aldose reductase inhibitors on the progression of retinopathy in galactose-fed dogs. Exp Eye Res. 1990;50:635-639.
7. Miwa K, Nakamura J, Hamada Y, et al. The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract. 2003;60:1-9.
8. Kubo E, Miyoshi N, Fukuda M, Akagi Y. Cataract formation through the polyol pathway is associated with free radical production. Exp Eye Res. 1999;68:457-464.
9. Yamagishi S, Nakamura K, Matsui T. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr Drug Discov Technol. 2006;3:83-88.
10. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007;55:498-510.
11. Obrosova IG, Pacher P, Szabó C, et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes. 2005;54:234-242.
12. Zheng L, Szabó C, Kern TS. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-κB. Diabetes. 2004;53:2960-2967.
13. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets. 2005;6:511-524.
14. Obrosova IG, Minchenko AG, Vasupuram R, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes. 2003;52:864-871.
15. Akagi Y, Kador PF, Kuwabara T, Kinoshita JH. Aldose reductase localization in human retinal mural cells. Invest Ophthalmol Vis Sci. 1983;24:1516-1519.
16. Akagi Y, Terubayashi H, Millen J, Kador PF, Kinoshita JH. Aldose reductase localization in dog retinal mural cells. Curr Eye Res. 1986;5:883-886.
17. Hohman TC, Nishimura C, Robison WG Jr. Aldose reductase and polyol in cultured pericytes of human retinal capillaries. Exp Eye Res. 1989;48:55-60.
18. Naruse K, Nakamura J, Hamada Y, et al. Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Exp Eye Res. 2000;71:309-315.
19. Murata M, Ohta N, Fujisawa S, et al. Selective pericyte degeneration in the retinal capillaries of galactose-fed dogs results from apoptosis linked to aldose reductase-catalyzed galactitol accumulation. J Diabetes Complications. 2002;16:363-370.
20. Sato S, Secchi EF, Lizak MJ, et al. Polyol formation and NADPH-dependent reductases in dog retinal capillary pericytes and endothelial cells. Invest Ophthalmol Vis Sci. 1999;40:697-704.
21. El-Remessy AB, Bartoli M, Platt DH, Fulton D, Caldwell RB. Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci. 2005;118:243-252.
22. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest. 1996;97:2883-2890.
23. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes. 2004;53:2404-2411.
24. Orlidge A, D'Amore PA. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol. 1987;105:1455-1462.
25. Orlidge A, Saunders KB, Smith SR, D'Amore PA. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci U S A. 1989;86:4544-4548.
26. Barnard JA, Lyons RM, Moses HL. The cell biology of transforming growth factor beta. Biochim Biophys Acta. 1990;1032:79-87.
27. Miyazono K, Hellman U, Wernstedt C, Heldin CH. Latent high molecular weight complex of transforming growth factor beta 1: purification from human platelets and structural characterization. J Biol Chem. 1988;263:6407-6415.
28. Wakefield LM, Smith DM, Flanders KC, Sporn MB. Latent transforming growth factor-beta from human platelets: a high molecular weight complex containing precursor sequences. J Biol Chem. 1988;263:7646-7654.
29. Gitlin JD, D'Amore PA. Culture of retinal capillary cells using selective growth media. Microvasc Res. 1983;26:74-80.
30. Folkman J, Haudenschild CC, Zetter BR. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci U S A. 1979;76:5217-5221.
31. Herman IM, D'Amore PA. Microvascular pericytes contain muscle and nonmuscle actins. J Cell Biol. 1985;101:43-52.
32. Guerrant GO, Moss CW. Detection by gas chromatography of 3-deoxy-D-manno-2-octulosonic acid and L-glycero-D-manno-heptose in whole cells of Neisseria elongata. J Clin Microbiol. 1986;23:425-430.
33. Lawrence DA, Pircher R, Kryceve-Martinerie C, Jullien P. Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol. 1984;121:184-188.
34. Kinoshita JH. A thirty year journey in the polyol pathway. Exp Eye Res. 1990;50:567-573.
35. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during coculture. J Cell Biol. 1989;109:309-315.
36. Sato Y, Okada F, Abe M, et al. The mechanism for the activation of latent TGF-beta during coculture of endothelial cells and smooth muscle cells: cell-type specific targeting of latent TGF-beta to smooth muscle cells. J Cell Biol. 1993;123:1249-1254.
37. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol. 1990;110:1361-1367.
38. Flaumenhaft R, Abe M, Mignatti P, Rifkin DB. Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells: regulation of plasminogen activator activity. J Cell Biol. 1992;118:901-909.
39. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A. 1993;90:1814-1818.
40. Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol. 2003;23:532-543.
41. Ishii H, Tada H, Isogai S. An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured mesangial cells. Diabetologia. 1998;41:362-364.
42. Engerman RL, Pfaffenbach D, Davis MD. Cell turnover of capillaries. Lab Invest. 1967;17:738-743.
43. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy: Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol. 1990;108:1234-1244.
44. D'Amore PA. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci. 1994;35:3974-3979.
45. McAvoy JW, Chamberlain CG. Growth factors in the eye. Prog Growth Factor Res. 1990;2:29-43.
46. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A. Deficient activation and different expression of transforming growth factor-beta isoforms in active proliferative diabetic retinopathy and neovascular eye disease. Exp Clin Endocrinol Diabetes. 1999;107:21-28.
47. Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes. 1997;46:26-30.